Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings results today. Reported sales increased 5.3% year-over-year to $22.5 billion. Operational sales growth was 6.7%. Net earnings decreased 17% to $3.4 billion, or $1.41 per share, compared to last year. Adjusted EPS decreased 10.9% to $2.04. Revenue surpassed projections while earnings came in line […]
“Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings results today. Reported sales increased 5.3% year-over-year to $22.5 billion. Operational sales growth was 6.7%. Net earnings decreased 17% to $3.4 billion, or $1.41 per share, compared to last year. Adjusted EPS decreased 10.9% to $2.04. Revenue surpassed projections while earnings came in line […]
· January 22, 2025
Johnson & Johnson (NYSE: JNJ) reported its fourth quarter 2024 earnings results today.
Reported sales increased 5.3% year-over-year to $22.5 billion. Operational sales growth was 6.7%.
Net earnings decreased 17% to $3.4 billion, or $1.41 per share, compared to last year. Adjusted EPS decreased 10.9% to $2.04.
Revenue surpassed projections while earnings came in line with estimates.
For full-year 2025, the company expects reported sales of $89.2-90.0 billion and adjusted EPS of $10.50-10.70.
The stock stayed red in premarket hours on Wednesday.
